Search Results - "Andrew Faller, Bryan"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

    Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, Howard S., Catalano, Paul J., O'Dwyer, Peter J., Mitchell, Edith P., Cohen, Deirdre Jill, Faller, Bryan Andrew, Kortmansky, Jeremy S., Kircher, Sheetal Mehta, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N., Benson, Al Bowen

    Published in Journal of clinical oncology (20-05-2018)
    “…Abstract only…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

    O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, H, Catalano, Paul J, O'Dwyer, Peter J, Mitchell, Edith P, Jill Cohen, Deirdre, Andrew Faller, Bryan, Kortmansky, Jeremy S, Mehta Kircher, Sheetal, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N, Bowen Benson III, Al

    Published in Annals of oncology (01-06-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

    Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, H., Catalano, Paul J., O'Dwyer, Peter J., Mitchell, Edith P., Jill Cohen, Deirdre, Andrew Faller, Bryan, Kortmansky, Jeremy S., Mehta Kircher, Sheetal, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N., Bowen Benson, Al

    Published in Annals of oncology (01-06-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: